On May 19, the Wall Street Journal revisited industry and patient relationships leading up to FDA approval of Sarepta’s eteplirsen. Chris Smith weighs in.
Read More
Last month’s World Orphan Drug Congress generated discussion on a wide range of hot topics, from gene therapy to pricing policies. The Rare Collective™ offers their insights.
RARE COLLECTIVE® is a trademark of Rare Collective, LLC. 